Stock listing
KRX:308080 ViGenCell, Inc. (바이젠셀) 주가
Follow ViGenCell, Inc. into a list and get an email when it puts out news.
Share price · KRX:308080
₩4,010.00 KRW -230.00 (-5.4%)
Close on Nov 20, 2026
- Day range
- ₩3,980.00 – ₩4,145.00 KRWNov 20, 2026
- Volume
- 83,425 sharesNov 20, 2026
- Market cap
- ₩82.20B KRWAt the close on Nov 20, 2026 · price × 20.50M shares outstanding
- 52-week range
- ₩3,070.00 – ₩17,360.00 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ₩970.3M KRWMedian day 85,073 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:308080 · KRW, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₩4,010.00 | -230.00 | -5.4% | ₩4,080.00 | ₩4,145.00 | ₩3,980.00 | 83,425 | |
| ₩4,240.00 | -155.00 | -3.5% | ₩4,305.00 | ₩4,340.00 | ₩4,030.00 | 312,193 | |
| ₩4,395.00 | +120.00 | +2.8% | ₩4,265.00 | ₩5,550.00 | ₩4,200.00 | 1,253,250 | |
| ₩4,275.00 | -245.00 | -5.4% | ₩4,520.00 | ₩4,645.00 | ₩4,270.00 | 76,970 | |
| ₩4,520.00 | -180.00 | -3.8% | ₩4,700.00 | ₩4,790.00 | ₩4,490.00 | 68,057 | |
| ₩4,700.00 | -275.00 | -5.5% | ₩5,090.00 | ₩5,100.00 | ₩4,580.00 | 81,870 | |
| ₩4,975.00 | +85.00 | +1.7% | ₩4,850.00 | ₩5,200.00 | ₩4,850.00 | 84,868 | |
| ₩4,890.00 | +75.00 | +1.6% | ₩4,815.00 | ₩4,960.00 | ₩4,650.00 | 88,341 | |
| ₩4,815.00 | +445.00 | +10.2% | ₩4,365.00 | ₩5,130.00 | ₩4,280.00 | 265,852 | |
| ₩4,370.00 | -145.00 | -3.2% | ₩4,250.00 | ₩4,465.00 | ₩4,105.00 | 104,948 | |
| ₩4,515.00 | -80.00 | -1.7% | ₩4,595.00 | ₩4,750.00 | ₩4,400.00 | 76,342 | |
| ₩4,595.00 | +125.00 | +2.8% | ₩4,630.00 | ₩4,630.00 | ₩4,355.00 | 58,655 | |
| ₩4,470.00 | -220.00 | -4.7% | ₩4,690.00 | ₩4,725.00 | ₩4,465.00 | 53,416 | |
| ₩4,690.00 | +35.00 | +0.8% | ₩4,655.00 | ₩4,760.00 | ₩4,625.00 | 39,088 | |
| ₩4,655.00 | -215.00 | -4.4% | ₩4,810.00 | ₩4,895.00 | ₩4,595.00 | 79,079 | |
| ₩4,870.00 | -170.00 | -3.4% | ₩5,180.00 | ₩5,180.00 | ₩4,865.00 | 95,225 | |
| ₩5,040.00 | -30.00 | -0.6% | ₩5,250.00 | ₩5,250.00 | ₩4,975.00 | 93,334 | |
| ₩5,070.00 | 0.00 | 0.0% | ₩5,190.00 | ₩5,200.00 | ₩5,000.00 | 78,066 | |
| ₩5,070.00 | +95.00 | +1.9% | ₩5,280.00 | ₩5,700.00 | ₩5,010.00 | 174,897 | |
| ₩4,975.00 | -55.00 | -1.1% | ₩5,070.00 | ₩5,070.00 | ₩4,805.00 | 55,859 | |
| ₩5,030.00 | -310.00 | -5.8% | ₩5,220.00 | ₩5,400.00 | ₩5,000.00 | 75,128 | |
| ₩5,340.00 | -10.00 | -0.2% | ₩5,300.00 | ₩5,600.00 | ₩5,270.00 | 62,398 | |
| ₩5,350.00 | -140.00 | -2.6% | ₩5,360.00 | ₩5,730.00 | ₩5,290.00 | 65,498 | |
| ₩5,490.00 | +50.00 | +0.9% | ₩5,210.00 | ₩5,540.00 | ₩5,210.00 | 62,269 | |
| ₩5,440.00 | +330.00 | +6.5% | ₩5,120.00 | ₩5,490.00 | ₩5,120.00 | 60,181 | |
| ₩5,110.00 | -310.00 | -5.7% | ₩5,160.00 | ₩5,350.00 | ₩5,000.00 | 96,706 | |
| ₩5,420.00 | -100.00 | -1.8% | ₩5,560.00 | ₩5,670.00 | ₩5,390.00 | 41,214 | |
| ₩5,520.00 | +20.00 | +0.4% | ₩5,450.00 | ₩5,750.00 | ₩5,020.00 | 154,622 | |
| ₩5,500.00 | -340.00 | -5.8% | ₩5,840.00 | ₩5,900.00 | ₩5,500.00 | 90,744 | |
| ₩5,840.00 | -60.00 | -1.0% | ₩5,850.00 | ₩5,920.00 | ₩5,700.00 | 63,309 | |
| ₩5,900.00 | +90.00 | +1.5% | ₩5,810.00 | ₩5,990.00 | ₩5,780.00 | 71,380 | |
| ₩5,810.00 | 0.00 | 0.0% | ₩5,880.00 | ₩6,060.00 | ₩5,760.00 | 65,306 | |
| ₩5,810.00 | -40.00 | -0.7% | ₩5,850.00 | ₩6,020.00 | ₩5,700.00 | 48,268 | |
| ₩5,850.00 | +90.00 | +1.6% | ₩5,760.00 | ₩5,960.00 | ₩5,600.00 | 115,179 | |
| ₩5,760.00 | +220.00 | +4.0% | ₩5,660.00 | ₩5,910.00 | ₩5,540.00 | 82,058 | |
| ₩5,540.00 | -230.00 | -4.0% | ₩5,800.00 | ₩5,890.00 | ₩5,450.00 | 98,823 | |
| ₩5,770.00 | +50.00 | +0.9% | ₩5,800.00 | ₩6,660.00 | ₩5,500.00 | 230,654 | |
| ₩5,720.00 | +130.00 | +2.3% | ₩5,590.00 | ₩5,790.00 | ₩5,510.00 | 68,316 | |
| ₩5,590.00 | +30.00 | +0.5% | ₩5,720.00 | ₩5,850.00 | ₩5,560.00 | 93,840 | |
| ₩5,560.00 | -150.00 | -2.6% | ₩5,680.00 | ₩5,730.00 | ₩5,490.00 | 83,459 | |
| ₩5,710.00 | -140.00 | -2.4% | ₩6,000.00 | ₩6,000.00 | ₩5,600.00 | 121,225 | |
| ₩5,850.00 | -40.00 | -0.7% | ₩5,910.00 | ₩5,960.00 | ₩5,770.00 | 78,410 | |
| ₩5,890.00 | -330.00 | -5.3% | ₩6,300.00 | ₩6,300.00 | ₩5,800.00 | 105,194 | |
| ₩6,220.00 | 0.00 | 0.0% | ₩6,150.00 | ₩6,390.00 | ₩6,090.00 | 85,278 | |
| ₩6,220.00 | -320.00 | -4.9% | ₩6,450.00 | ₩6,530.00 | ₩6,180.00 | 107,046 | |
| ₩6,540.00 | -200.00 | -3.0% | ₩6,570.00 | ₩6,860.00 | ₩6,480.00 | 86,484 | |
| ₩6,740.00 | -40.00 | -0.6% | ₩6,780.00 | ₩6,780.00 | ₩6,400.00 | 171,951 | |
| ₩6,780.00 | +100.00 | +1.5% | ₩6,750.00 | ₩6,840.00 | ₩6,500.00 | 108,189 | |
| ₩6,680.00 | +40.00 | +0.6% | ₩6,710.00 | ₩7,000.00 | ₩6,650.00 | 270,179 | |
| ₩6,640.00 | +60.00 | +0.9% | ₩6,580.00 | ₩6,910.00 | ₩6,310.00 | 171,445 | |
| ₩6,580.00 | +320.00 | +5.1% | ₩6,260.00 | ₩6,690.00 | ₩6,220.00 | 166,628 | |
| ₩6,260.00 | +80.00 | +1.3% | ₩6,200.00 | ₩6,500.00 | ₩6,100.00 | 190,176 | |
| ₩6,180.00 | -1,100.00 | -15.1% | ₩7,000.00 | ₩7,070.00 | ₩6,110.00 | 589,642 | |
| ₩7,280.00 | +1,230.00 | +20.3% | ₩6,000.00 | ₩7,860.00 | ₩5,940.00 | 2,449,508 | |
| ₩6,050.00 | +310.00 | +5.4% | ₩5,620.00 | ₩6,120.00 | ₩5,450.00 | 88,292 | |
| ₩5,740.00 | -10.00 | -0.2% | ₩5,880.00 | ₩5,880.00 | ₩5,560.00 | 74,941 | |
| ₩5,750.00 | +10.00 | +0.2% | ₩5,740.00 | ₩5,950.00 | ₩5,570.00 | 56,357 | |
| ₩5,740.00 | -50.00 | -0.9% | ₩5,810.00 | ₩6,090.00 | ₩5,680.00 | 71,460 | |
| ₩5,790.00 | +100.00 | +1.8% | ₩5,600.00 | ₩5,800.00 | ₩5,400.00 | 79,757 | |
| ₩5,690.00 | +290.00 | +5.4% | ₩5,480.00 | ₩5,800.00 | ₩5,310.00 | 88,125 | |
| ₩5,400.00 | -360.00 | -6.3% | ₩5,760.00 | ₩5,760.00 | ₩5,300.00 | 101,490 | |
| ₩5,760.00 | 0.00 | 0.0% | ₩6,050.00 | ₩6,170.00 | ₩5,450.00 | 83,372 |
Splits
1 split · KRX:308080 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 2-for-1 | Split |
- Ticker
- KRX:308080
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- KRX
- Currency
- KRW
ViGenCell, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
Valuation
EV/sales 65.1× against a median of 6.3×: 6th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- ₩60.05B KRW
- P/E
- Loss
- EV/sales
- 65.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.1×
- Gross margin
- 4.9%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.2×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| ViGenCell, Inc. · KRX:308080 | US$61.07M | US$44.61M | n/a | 65.1× | n/a | 2.1× | n/a | 0.2× | n/a |
| Lytix Biopharma ASA · OSL:LYTIX | US$63.10M | US$53.73M | n/a | n/a | n/a | 7.1× | n/a | 0.0× | n/a |
| Neumora Therapeutics, Inc. · NASDAQ:NMRA | US$63.01M | US$30.65M | n/a | 1,916× | n/a | 3.4× | n/a | 2.9× | 1.07 |
| Poolbeg Pharma PLC · LSE:POLB | US$61.42M | US$55.12M | n/a | n/a | n/a | 7.0× | n/a | 0.0× | n/a |
| vTv Therapeutics Inc. · NASDAQ:VTVT | US$61.33M | −US$15.84M | n/a | −0.4× | n/a | 0.9× | −20.8% | 0.0× | 1.28 |
| Oncopeptides AB · OMXSTO:ONCO | US$61.25M | US$59.05M | n/a | 6.3× | n/a | 25.1× | −223.6% | 5.4× | n/a |
| HemoGenyx Pharmaceuticals PLC · LSE:HEMO | US$60.45M | US$56.88M | n/a | n/a | n/a | 10.7× | n/a | 0.4× | n/a |
| Genexine, Inc. · KRX:095700 | US$60.01M | US$44.21M | n/a | 12.0× | n/a | 0.4× | −650.0% | 0.0× | n/a |
| GlycoNex, Inc. · TPEX:4168 | US$59.91M | US$57.19M | n/a | 84.9× | n/a | 2.3× | n/a | 0.6× | n/a |
| ISU Abxis Co., Ltd. · KRX:086890 | US$59.84M | US$42.28M | n/a | 1.1× | n/a | 0.7× | −16.0% | 0.0× | n/a |
| Rani Therapeutics Holdings, Inc. · NASDAQ:RANI | US$58.99M | US$16.85M | n/a | 2.6× | n/a | 1.7× | −493.0% | 0.1× | 2.21 |
| Median of the others | US$60.85M | US$48.97M | 6.3× | 2.9× | −223.6% | 0.1× | 1.28 |
Financials
Annual, in KRW
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 22.7M | 278.9M | 0 | 0 | 0 | 15.0M | |
| Cost of revenue | 11.6M | 267.1M | 0 | 0 | 0 | 0 | |
| Gross profit | 11.1M | 11.9M | 0 | 0 | 0 | 15.0M | |
| Research and development | 14.8B | 11.6B | 15.5B | 12.3B | 6.82B | 4.42B | |
| Selling, general and administrative | 407.5M | 2.92B | 3.54B | 1.13B | 5.38B | 3.09B | 2.32B |
| Operating income | -17.1B | -15.3B | -20.1B | -18.2B | -13.1B | -7.91B | -15.0B |
| Depreciation and amortization | 2.98B | 3.33B | 3.81B | 2.92B | 1.72B | 761.7M | 101.4M |
| EBITDA | -14.1B | -12.0B | -16.3B | -15.3B | -11.4B | -7.15B | -14.9B |
| Interest expense | 318.0M | 363.6M | 399.3M | 289.2M | 352.7M | 613.3M | 0 |
| Income before tax | -16.3B | -14.1B | -17.9B | -17.4B | -11.1B | -10.5B | -22.4B |
| Net income | -16.3B | -14.1B | -17.9B | -17.4B | -11.1B | -10.5B | -22.4B |
| Earnings per share, basic | -796.24 | -729.64 | -932.68 | -915.14 | -588.52 | -554.19 | -1,188.98 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.93B | 11.1B | 17.7B | 8.34B | 32.1B | 5.25B | 16.5B |
| Short-term investments | 29.5B | 34.1B | 35.7B | 60.7B | 33.3B | 10.9B | 8.12B |
| Receivables | 2.93M | 256.5M | 226.4M | 602.4M | 63.1M | 12.1M | 422.9K |
| Current assets | 34.2B | 45.9B | 54.4B | 69.9B | 66.7B | 17.7B | 24.9B |
| Property, plant and equipment | 18.8B | 23.5B | 27.0B | 16.1B | 2.82B | 862.5M | |
| Total assets | 54.3B | 67.3B | 81.0B | 99.4B | 117.0B | 23.1B | 26.5B |
| Current liabilities | 1.71B | 8.00B | 8.47B | 8.35B | 10.2B | 56.3B | 51.6B |
| Long-term debt | 7.40B | ||||||
| Total debt | 328.0M | ||||||
| Total liabilities | 10.6B | 9.32B | 9.56B | 9.73B | 12.1B | 57.1B | 51.8B |
| Shareholders' equity | 43.7B | 58.0B | 71.5B | 89.6B | 104.9B | -34.1B | -25.3B |
| Shares outstanding | 20.5M | 19.3M | 19.2M | 19.0M | 18.9M | 18.9M | 18.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -13.8B | -10.9B | -15.3B | -11.1B | -7.95B | -8.19B | -2.96B |
| Capital spending | -821.8M | -112.5M | -1.02B | -13.7B | -11.5B | -1.77B | -987.5M |
| Free cash flow | -14.6B | -11.0B | -16.3B | -24.8B | -23.4B | -9.97B | -3.95B |
| Cash from investing | 4.11B | 24.3B | -10.9B | -68.7B | -2.65B | -6.19B | |
| Cash from financing | 169.5M | 296.7M | -1.82B | 103.6B | -379.4M | 20.0B | |
| Share buybacks | 215.6M | 314.0M | 78.5M | 95.2B | 20.0B | ||
| Change in cash | -7.14B | -6.62B | 9.35B | -23.8B | 26.9B | -11.2B | 10.8B |
Cap table
Built by 6ix from ViGenCell, Inc.’s releases
- Common shares
- 20,499,260
- Fully diluted
- 20,499,260
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 20,499,260 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 20,499,260 |
Log in to ask 6ix AI your own questions about ViGenCell, Inc.